The Centers for Medicare & Medicaid Services (CMS) announced the selection of 15 high-cost prescription drugs covered under Medicare Part D and, for the first time, drugs payable under Medicare Part B for the third cycle of the Medicare Drug Price Negotiation Program (MDPNP). CMS also selected one previously negotiated drug for the program's first renegotiations. Negotiations with participating drug companies will occur in 2026 and any negotiated and renegotiated prices will become effective Jan. 1, 2028.
The selected drug list for the third cycle of negotiations is: Anoro Ellipta; Biktarvy; Botox/Botox Cosmetic; Cimzia; Cosentyx; Entyvio; Erleada; Kisqali; Lenvima; Orencia; Rexulti; Trulicity; Verzenio; Xeljanz/Xeljanz XR; and Xolair. The selected drug for renegotiation is Tradjenta.
CMS has also released a list of 50 top negotiation-eligible drugs based on combined expenditures under Medicare Parts B and D. The drugs selected for the third cycle represent the top 15 highest-spending drugs on this list.
See here for a fact sheet on the drugs selected for negotiation and renegotiation. See here for the list of National Drug Codes (NDCs) associated with drugs currently in the MDPNP, which represents the NDCs for which any negotiated maximum fair price would apply consistent with CMS guidance.
For resources and NCPA advocacy on the MDPNP, see here.
